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Abstract

Introduction
Achilles tendinopathy (AT) is a cause of pain and disability affecting both athletes and sedentary individuals. More than 85,000 patients present to primary care with AT annually.
Whilst there is much preclinical work on the use of stem cells in tendon pathology, there is a scarcity of clinical data looking at the use of mesenchymal stem cells to treat tendon disease and there does not appear to be any studies of the use of autologous cultured mesenchymal stem cells (MSCs) for Achilles tendinopathy. Our hypothesis is that autologous culture expanded MSCs implanted into an area of midportion AT will lead to improved pain-free mechanical function. The current paper presents the protocol for a phase IIa clinical study.
Methods and analysis
The presented protocol is for a non-commercial, single arm, open-label, phase IIa proof of concept study. The study will recruit 10 participants and will follow them up for 6-months.
Included will be patients aged 18 to 70 with chronic midportion AT who have failed at least 6 months of non-operative management. Participants will have a bone marrow aspirate collected from the posterior iliac crest under either local or general anaesthetic. MSCs will be isolated and expanded from the bone marrow. Four to six weeks after the harvest, participants will undergo implantation of the culture expanded MSCs under local anaesthetic and ultrasound guidance. The primary outcome will be safety as defined by the incidence rate of Serious Adverse Reaction (SAR). The secondary outcomes will be efficacy as measured by patient reported outcome measures and radiological outcome using ultrasound techniques. 
Ethics and dissemination
The protocol has been approved by the National Research Ethics Service Committee (London, Harrow -reference 13/LO/1670). Trial findings will be disseminated through peerreviewed publications and conference presentations.
Trial Registration
Registered on ClinicalTrials.gov 17th Febuary 2014, NCT02064062
Strengths and limitations of this study
• First study of its kind injecting culture expanded MSCs into midportion AT.
• Capturing both clinical scores and radiological outcomes.
• MSC implantation is ultrasound guided.
• Independent assessment using Ultrasound Tissue Characteristics (UTC).
• Proof of concept safety study therefore further research will be required. 
Introduction
The Achilles tendon is the largest tendon in the body and it plays an important role in the biomechanics of the lower extremity. It can withstand great forces, especially during sporting exercise. More than 85,000 patients present to primary care with Achilles Tendinopathy (AT)
annually (General Practitioner Research Database 2007) . This is a degenerative process that leads to pain and dysfunction in middle-aged individuals and sports participants. [1] Tendinopathic tendons lose their shiny appearance and microscopy reveals discontinuous and disorganised collagen fibres. This is associated with mucoid and lipoid degeneration and an increasing number of cells within the tendon tissue, mostly with a fibroblastic or myofibroblastic appearance. Often, there is an abrupt discontinuity of both vascular and myofibroblastic proliferation immediately adjacent to the area of greatest abnormality.
Achilles tendon degeneration is evident as an increased signal on Magnetic Resonance
Imaging (MRI) [2] and as hypoechogenic regions on ultrasound investigation. [3] These areas of abnormal imaging correspond with areas of altered collagen fibre structure and increased interfibrillar ground substance, which has been shown to consist of hydrophilic glycosaminoglycans. [2] Achilles tendinopathy adversely affect quality of life by causing chronic pain and disability.
The source of pain has been associated with neurovascular ingrowth and autocrine/paracrine effect of cellular products (e.g. catecholamines, acetylcholine, glutamate) and a reduction in pain is a key indicator of treatment success. [4] Numerous management strategies exist for AT, such as rest, physiotherapy with eccentric strengthening exercises, [5] extracorporeal shockwave therapy, [6] dry needling, [6] high volume injections, [6] and platelet rich plasma injections. [7] However, apart from eccentric loading exercises none of these therapies have been shown to be more effective than placebo [6] A recent randomised controlled trial (RCT) demonstrated that the use of platelet-rich plasma had no statistically significant advantage over a saline placebo group. [7, 8] Although the majority of tendon conditions are treated non-operatively, up to 45% of patients at some stage consider surgery. [4] Tendon disorders are a major burden on the National Health Service (NHS). 51,454 operations on tendon disorders were performed in the NHS in 2015/16 (HESOnline), which is up from 48,765 operations performed in 2004/5. Given that the majority of tendon problems are treated non-operatively, this high surgical caseload represents just the tip of the iceberg of the real cost to the health service of tendon disease.
There is therefore a need for safe and effective non-surgical treatments.
Laboratory based studies looking at autologous mesenchymal stem cells (MSCs) injections into damaged tendons have shown improved functional and histological outcomes. [9] [10] [11] [12] Smith et al published an equine case-control trial comparing autologous bone marrow derived MSCs and saline injections. The treated tendons exhibited statistically significant improvements in key parameters with normalisation of biomechanical, morphological, and compositional parameters. [13] Another study followed up 141 horses post intralesional MSC injection for digital flexor tendinopathy. Two year follow up showed no adverse effects of the treatment with no aberrant tissue on histological examination. The re-injury percentage was significantly less than published for national hunt racehorses treated in other ways. [11] Human studies using MSCs have shown promise in many conditions including heart disease, [14] musculoskeletal disorders, [15] autoimmune diseases, [16] and neurological disorders. [17] With regards the use of MSCs in human tendons, there are only a handful of reports. Gomes et al performed a cohort study in 14 patient that received Bone marrow concentrate (BMC) derived from the iliac crest with rotator cuff repair. 12 months following the procedure all patients had better clinical scores and MRI showed that tendons had healed. [18] Hernigou et al performed a study comparative study looking at effect of BMC cells on rotator cuff healing post arthroscopic repair. Patients treated with BMC had a significantly increased healing rate and a significant reduction in re-rupture. [19] In contrast Mazzocca et al used BMCs from the humeral head with a similar model of rotator cuff repair, and showed no statistical difference in clinical outcome at a mean of 10.6 months. [20] Pascual-Garrido et al looked at 8 patients with patella tendinopathy. BMCs from the iliac crest were injected into the patella tendon under ultrasound guidance. At a mean follow-up of 5 years there was significant improvement in most clinical scores. This improvement was seen up to year 2 after which it plateaued. Ultrasound evaluation was at 6 months showed that 8 of the 9 patient had improvement in the grading of the patella tendinopathy. [21] Singh et al looked at 30 patients with untreated tennis elbow. BMCs from iliac crest were injected into the lateral epicondyle. There was a statistically significant improvement in the Patient-rated Tennis Elbow Evaluation score at 12 weeks. [22] All of these studies used mononuclear cells from bone marrow concentrate. We could only identify one study looking at culture expanded MSCs in Achilles tendinopathy. Ilic et al reported the use of human placenta-derived allogenic MSCs injected under ultrasound guidance in 6 patients. They monitored for the primary outcome, which was safety. They concluded it was safe to inject human placenta-derived MSCs into human achilles tendons however made no comment on clinical outcome. [23] There is clearly a lack of reliable evidence for the use of MSCs in tendon disease. Our hypothesis is that autologous culture expanded MSCs implanted into a tendon with Achilles tendinopathy will lead to improvement in pain-free mechanical function. The current paper presents the protocol for phase IIa trial to explore this.
Methods and Analysis
Study design
Following dialogue and engagement with the Medicines and Healthcare Regulatory Agency (MHRA) the trial was defined as a non-commercial, single arm, open-label, phase IIa proof of concept study. The study will be conducted at the Royal National Orthopaedic Hospital (RNOH). The study will recruit 10 participants and will follow them up for 6-months ( Figure   1 ).
The primary outcome will be safety as defined by the incidence rate of Serious Adverse Reaction (SAR). The secondary outcomes will be efficacy as measured by patient reported outcome measures. Ultrasound techniques will assess the radiological outcome of the procedure. The end of the ASCAT trial is the last visit of the last participant.
Inclusion criteria
Patients aged 18 to 70 (both males and females) with chronic midportion AT (defined by pain and tender swelling in mid portion of AT (more than 1cm proximal to the insertion), with symptoms for longer than 6 months who have failed conservative treatment (at least a full course of physiotherapy) and for whom surgery is being considered. All participants must be able to provide written informed consent. Females of childbearing age and potential must be willing to use two forms of effective contraception from the time of consent to 6 months post-injection (Table 1) .
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Recruitment and consent
Patients who are referred to the RNOH will be identified as potentially eligible for the trial by the Chief Investigator (CI) or delegated clinician and invited to participate. The RNOH is a tertiary referral centre for AT and potential participants will be referred by letter to the Foot and Ankle department at the RNOH. The CI or delegated clinicians at the Foot and Ankle department will review referral letters. In the main, it may not be possible to identify relevant patients with chronic midportion AT from the referral letters; however Patient Information Sheets (PIS) may be sent by post or email to referred patients informing them of the trial. The CI or delegate will wait until the patient is seen in the initial outpatient consultation to explain the trial in more detail and if they are eligible invite them to participate. Participant Identification Centres (PIC) will also be used to identify potential patients for the trial and these may include primary care musculoskeletal triage services. Potential participants will be referred by the PIC to the trial site.
Screening Assessments
Pre-screening interview will include a medical history with discussion about willingness to participate in the trial. This will be followed by a clinical assessment that will include a and a routine examination of the foot and ankle, including; inspection of limb alignment and other biomechanical abnormality such as flat or high arched feet; size and location of swelling over the Achilles tendon and range of motion of the ankles, hindfeet, midfeet and forefeet.
Assessment of gastrocnemius tightness will be performed with the knee fully straight and flexed 20 degrees (Silfverskiold test). Examination will aim to rule out other conditions such as an adjacent bursitis or insertional tendinopathy (tenderness over the calcaneal bony attachment). The Simmonds' test will be performed to ensure continuity of the tendon. 
Baseline Assessment
Baseline assessments to be carried out on day 0, immediately prior to harvest include: • Adverts Events (AE) review Table 2 shows all the planned assessments and procedures that will be performed before MSC implantation. Approximately five weeks after bone marrow harvest, participants will undergo implantation of the culture expanded MSCs under local anaesthetic in the outpatient setting following clinical assessment and tendon imaging using conventional ultrasound and Ultrasound Tissue Characterisation (UTC) measurement. [24] A single injection of between 4-20x10 6 MSCs suspended in 1ml of Dulbecco's Modified
Eagles Medium (DMEM) will be injected under ultrasound control by a delegated, experienced and trained radiologist along the length of the tendon at the area of greatest degeneration starting just distal to the degeneration and finishing just proximal to normal structure. Participants will be observed for a minimum of 2 hours after implantation for any immediate adverse effects.
All participants will be referred for a standard course of physiotherapy. The physiotherapist will issue a discharge summary following their treatment and a copy of this will be included in the participant record. This summary includes details on participant compliance.
Subsequent assessments
Subsequent assessments following the MSC implantation include adverse event review, VAS (pain) score, MOXFQ, VISA-A questionnaire, EQ-5D, SAS questionnaire, ultrasound imaging (conventional ultrasound and UTC), and clinical assessment ( Table 2 ). These will 
Statistical analysis
The findings from this study will be published and the data will also be included in subsequent larger trials if appropriate. Baseline data collected and summarised, this will include: participant gender, age, height, weight, BMI, duration of symptoms, sporting activity, smoking/non-smoking, medication, any other musculoskeletal problems, EQ-5D, MOXFQ, VAS (pain) score, SAS score, VISA-A score, and ultrasound findings (conventional ultrasound and UTC findings). Continuous baseline data will be presented as mean and standard deviation for normally distributed variables, medians and interquartile ranges for non-normally distributed variables and frequencies and percentages for categorical baseline variables. For the primary outcome the proportion of participants experiencing a SAR at any time over the 24-week follow-up period will be calculated along with exact binomial confidence intervals to express the uncertainty in the observed incidence rate of SAR.
Since the primary outcome is the incidence of SARs missing outcomes are not anticipated.
The primary analysis will be as per-protocol. All participants will receive the same treatment which cannot be withdrawn once given and we will only analyse the data from the participants who actually receive autologous culture expanded MSCs. Cancellation of implantation will be a logistical rather than surgical decision and as such is not expected to introduce bias. The proportion of participants experiencing a success at 6 months will be calculated along with exact binomial confidence intervals to express the uncertainty in the observed incidence of success at 6 months. Changes from baseline in EQ-5D, MOXFQ, VAS (pain) score, VISA-A and SAS scores will be summarised as mean and standard deviation if normally distributed, or median and interquartile range if the data does not demonstrate normality.
Ethics and dissemination
Ethics approval was granted 23/12/13 by the NRES Committee London-Harrow. (REC reference -13/LO/1670). The findings of this study will be disseminated through peerreviewed publications and conference presentations. 
Competing interests
None declared.
Acknowledgments
Louise Kim for helping with the grant applications, Michelle Korda for tireless efforts on the protocol, and Deirdre Brooking for the refinement of the protocol and initiation of the trial.
Thanks also to Dr Hans van Schie, for his expert advice on the UTC system and to Mark
Lowdell for the development of the stem cells culture protocols. We would also like to thank Iva, Ufedo and Vandana at RNOH research department for their innovation advice. Tables   Table 1 Inclusion and Exclusion criteria for the study   Inclusion criteria 1. Aged ≥18 and ≤ 70 (both males and females) 2. Participants with chronic midportion AT (as defined by pain in region of AT and tender swelling in mid portion of the AT with symptoms for longer than 6 months who have failed conservative treatment (at least a full course of physiotherapy) and for whom surgery is being considered 3. Able to provide written informed consent 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 
Exclusion criteria
1. Previous bony surgery (e.g. reconstructive pelvic osteotomy) at or in proximity to the bone marrow harvest site 2. Pregnancy or lactation (self declaration at screening visit with follow up urine pregnancy test to be confirmed not beyond 7 days prior to MSC harvest and administration) 3. Current use of steroids, anti-TNF drugs, methotrexate, or ciprofloxacin (or use within 4 weeks of assessment for eligibility) 4. Positive for HBV, HCV, HIV 1 and 2, syphilis and HTLV 5. Previous AT surgery on the tendon to receive MSC implantation 6. Inflammatory arthritis 7. Known or suspected underlying haematological malignancy 8. Other active malignancy in the past 3 years 9. Bovine or antibiotic allergy (since these are in the culture medium) 
*** Self declaration from the patient X Urine pregnancy test at Bone Marrow Harvest ** Screening procedures must take place at least 1 week before and within 30 days of the bone marrow procedure § Day 2 follow-up assessments are done by telephone ¶ Within 7 days of implantation X 4 Two radiologists will independently scan the participant using US. UTC will also be measured twice on each occasion. X The number of visits are dependent on participant's progress and are not obligatory at these time points. Standard NHS protocol for physiotherapy will start within one to two weeks after implantation. Dates of physiotherapy attendances will be recorded in the case report form (CRF). 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 
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Methods and analysis
Included will be patients aged 18 to 70 with chronic midportion AT who have failed at least 6 months of non-operative management. Participants will have a bone marrow aspirate collected from the posterior iliac crest under either local or general anaesthetic. MSCs will be isolated and expanded from the bone marrow. Four to six weeks after the harvest, participants will undergo implantation of the culture expanded MSCs under local anaesthetic and ultrasound guidance. The primary outcome will be safety as defined by the incidence rate of Serious Adverse Reaction (SAR). The secondary outcomes will be efficacy as measured by patient reported outcome measures and radiological outcome using ultrasound techniques.
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Ethics and dissemination
Trial Registration
Strengths and limitations of this study
• A First -In-Man safety study
• Proof of concept safety study therefore further research will be required.
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Introduction
The Achilles tendon is the largest tendon in the body and it plays an important role in the biomechanics of the lower extremity. It can withstand great forces, especially during sporting exercise. The general population has an incidence of 2.35 per 1000 people, equivalent to more than 150 000 people in the United Kingdom every year. [1] This is a degenerative process that leads to pain and dysfunction in middle-aged individuals and sports participants. [2] Tendinopathic tendons lose their shiny appearance and microscopy reveals discontinuous and disorganised collagen fibres. This is associated with mucoid and lipoid degeneration and an increasing number of cells within the tendon tissue, mostly with a fibroblastic or myofibroblastic appearance. Often, there is an abrupt discontinuity of both vascular and myofibroblastic proliferation immediately adjacent to the area of greatest abnormality. [3] Achilles tendon degeneration is evident as an increased signal on Magnetic Resonance Imaging (MRI) [4] and as hypoechogenic regions on ultrasound investigation. [5] These areas of abnormal imaging correspond with areas of altered collagen fibre structure and increased interfibrillar ground substance, which has been shown to consist of hydrophilic glycosaminoglycans. [4] Achilles tendinopathy adversely affect quality of life by causing chronic pain and disability. [6] The source of pain has been associated with neurovascular ingrowth and autocrine/paracrine effect of cellular products (e.g. catecholamines, acetylcholine, glutamate) and a reduction in pain is a key indicator of treatment success. [3] Numerous management strategies exist for AT, such as rest, physiotherapy with eccentric strengthening exercises, [7] extracorporeal shockwave therapy, [8] dry needling, [8] high [8] and platelet rich plasma injections. [9] However, apart from eccentric loading exercises none of these therapies have been shown to be more effective than placebo (Magnussen et al, 2009 ). [8] The use of PRP is controversial. One randomised controlled trial looked at PRP versus stromal vascular fraction (SVF) derived from adipose. SVF has been shown to be source of MSCs. They showed that the use of PRP and SVF was safe and that both PRP and SVF improved clinical scores with statistical significance. The use of SVF seemed to provide quicker improvement but at 180 days there was no difference between the two groups. [10] Another randomised controlled trial (RCT) demonstrated that the use of platelet-rich plasma had no statistically significant advantage over a saline placebo group. [9, 11] Although the majority of tendon conditions are treated non-operatively, up to 45% of patients at some stage consider surgery. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 F o r p e e r r e v i e w o n l y 6 treatment with no aberrant tissue on histological examination. The re-injury percentage was significantly less than published for national hunt racehorses treated in other ways. [14] Human studies using MSCs have shown promise in many conditions including heart disease, [17] musculoskeletal disorders, [18] autoimmune diseases, [19] and neurological disorders. [20] With regards the use of MSCs in human tendons, there are only a handful of reports.
Gomes et al performed a cohort study in 14 patient that received Bone marrow concentrate (BMC) derived from the iliac crest with rotator cuff repair. 12 months following the procedure all patients had better clinical scores and MRI showed that tendons had healed. [21] Hernigou et al performed a study comparative study looking at effect of BMC cells on rotator cuff healing post arthroscopic repair. Patients treated with BMC had a significantly increased healing rate and a significant reduction in re-rupture. [22] In contrast Mazzocca et al used BMCs from the humeral head with a similar model of rotator cuff repair, and showed no statistical difference in clinical outcome at a mean of 10.6 months. [23] Pascual-Garrido et al looked at 8 patients with patella tendinopathy. BMCs from the iliac crest were injected into the patella tendon under ultrasound guidance. At a mean follow-up of 5 years there was significant improvement in most clinical scores. This improvement was seen up to year 2 after which it plateaued. Ultrasound evaluation was at 6 months showed that 8 of the 9 patient had improvement in the grading of the patella tendinopathy. [24] Singh et al looked at 30 patients with untreated tennis elbow. BMCs from iliac crest were injected into the lateral epicondyle. There was a statistically significant improvement in the Patient-rated Tennis Elbow Evaluation score at 12 weeks. [25] Page 6 of 22
All of these studies used mononuclear cells from bone marrow concentrate. Usielli et at published a study looking at PRP and SVF. The study concluded that SVF was safe and as efficacious as PRP at 180 days, although this study did not use culture expanded MSCs . [10] .
We could only identify one study looking at culture expanded MSCs in Achilles tendinopathy. Ilic et al reported the use of human placenta-derived allogenic MSCs injected under ultrasound guidance in 6 patients. They monitored for the primary outcome, which was safety. They concluded it was safe to inject human placenta-derived MSCs into human achilles tendons however made no comment on clinical outcome. [26] There is clearly a lack of reliable evidence for the use of MSCs in tendon disease. Our hypothesis is that autologous culture expanded MSCs implanted into a tendon with Achilles tendinopathy will lead to improvement in pain-free mechanical function. The current paper presents the protocol for phase IIa trial to explore this.
Methods and Analysis
Study design
Following dialogue and engagement with the Medicines and Healthcare Regulatory Agency (MHRA) the trial was defined as a non-commercial, single arm, open-label, phase IIa proof of concept study. The study will be conducted at the Royal National Orthopaedic Hospital (RNOH). The study will recruit 10 participants and will follow them up for 6-months ( Figure   1 ). The MHRA considered this study to be a First In Man (Phase IIa) study whose primary role was to demonstrate safety and hence all patients were to get the active treatment and no control group was used. The information from this study would then be used to design a subsequent phase III RCT involving a control.
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Reaction (SAR). The secondary outcomes will be efficacy as measured by patient reported outcome measures. Ultrasound techniques will assess the radiological outcome of the procedure. Computerized "Ultrasound Tissue Characterization" (UTC) is also carried out in order to add in a less subjective assessment. UTC involves a precision instrument that moves the ultrasound probe automatically across the long axis of the Achilles tendon collecting transverse images at even distances of 0.2 mm over a length of 12 cm. and enable tomographic visualization and tissue characterization and quantification of architecture and integrity of the collagenous matrix.
Ultrasound examinations undertaken in this study will performed by a musculoskeletal radiologist with experience of undertaking such an examinations. The end of the ASCAT trial is the last visit of the last participant.
Inclusion criteria
Recruitment and consent
Patients who are referred to the RNOH will be identified as potentially eligible for the trial by the Chief Investigator (CI) or delegated clinician and invited to participate. The RNOH is a tertiary referral centre for AT and potential participants will be referred by letter to the Foot
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and Ankle department at the RNOH. The CI or delegated clinicians at the Foot and Ankle department will review referral letters. In the main, it may not be possible to identify relevant patients with chronic midportion AT from the referral letters; however Patient Information Sheets (PIS) may be sent by post or email to referred patients informing them of the trial. The CI or delegate will wait until the patient is seen in the initial outpatient consultation to explain the trial in more detail and if they are eligible invite them to participate. Participant Identification Centres (PIC) will also be used to identify potential patients for the trial and these may include primary care musculoskeletal triage services. Potential participants will be referred by the PIC to the trial site.
Screening Assessments
Assessment of gastrocnemius tightness will be performed with the knee fully straight and flexed 20 degrees (Silfverskiold test). Examination will aim to rule out other conditions such as an adjacent bursitis or insertional tendinopathy (tenderness over the calcaneal bony attachment). The Simmonds' test will be performed to ensure continuity of the tendon. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 F o r p e e r r e v i e w o n l y 10 Viruses (HTLV). These tests will be carried out at least 1 week before (and within 30 days of the bone marrow harvest procedure) in line with the regulations. Additionally, a pregnancy test will be carried out prior to the bone marrow harvest (within 1 week) if the participant is a female of childbearing age and potential. If any of these tests are positive the participant will be counselled and deemed ineligible for the trial.
Baseline Assessment
Baseline assessments to be carried out on day 0, immediately prior to harvest include: • Adverts Events (AE) review Table 2 shows all the planned assessments and procedures that will be performed before MSC implantation.
Treatment Procedure
For eligible participants, approximately 8ml of bone marrow aspirate will be collected from the posterior iliac crest into a heparinized syringe under either local or general anaesthetic. A decision on which technique will be used will depend on discussions with the patient. MSC processing and manufacturing will be at the cell-processing centre at the Centre for Cell Gene A single injection of between 4-20x10 6 MSCs suspended in 1ml of Dulbecco's Modified
Subsequent assessments
Subsequent assessments following the MSC implantation include adverse event review, VAS (pain) score, MOXFQ, VISA-A questionnaire, EQ-5D, SAS questionnaire, ultrasound imaging (conventional ultrasound and UTC), and clinical assessment ( Table 2 ). These will occur at 6, 12 and 24 weeks post MSC implantation. After 2 days the trial coordinator will phone the patient to check they are well and record any adverse events on the ASCAT case report form. The trial will end on the last visit of the last precipitant. 
Patient and Public Involvement
Patients and the public were not directly involved with the development of the current protocol. The primary research question is the safety of use of culture expanded MSCs. This will enable the development of a larger RCT that will involve oversight from the patient and public representatives. Patient recruitment is described above and the results will be disseminated to the participants via a news letter.
Power and sample size
Sample size was determined to ensure a pre-determined level of accuracy for the incidence of Serious Adverse Reactions (SAR) using an exact binomial confidence interval. With 10 participants, if no SAR is observed we can rule out a true SAR rate of 31% or greater with 95% confidence, or a true SAR rate of 21% or greater with 80% confidence, or a true SAR rate of 13% or greater with 50% confidence. With 6 participants for the interim analysis, if no SAR is observed we can rule out a true SAR rate of 46% or greater with 95% confidence, or a true SAR rate of 32% or greater with 80% confidence, or a true SAR rate of 21% or greater with 50% confidence. Since the study is a proof of concept pilot study no formal power calculation was performed.
Statistical analysis
The findings from this study will be published and the data will also be included in subsequent larger trials if appropriate. Baseline data collected and summarised, this will include: participant gender, age, height, weight, BMI, duration of symptoms, sporting activity, smoking/non-smoking, medication, any other musculoskeletal problems, EQ-5D, MOXFQ, VAS (pain) score, SAS score, VISA-A score, and ultrasound findings Continuous baseline data will be presented as mean and standard deviation for normally distributed variables, medians and interquartile ranges for non-normally distributed variables and frequencies and percentages for categorical baseline variables. For the primary outcome the proportion of participants experiencing a SAR at any time over the 24-week follow-up period will be calculated along with exact binomial confidence intervals to express the uncertainty in the observed incidence rate of SAR.
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